Humoral immunity

Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Conference, Rituximab, B-cell lymphoma, Serum, HIO, Patient, CD20, Humoral immunity, Cancer, BRITE, NHL, AACR, CA125, ADC, Lymphoma, CD19, Vaccine

Recent clinical evidence suggests that high serum levels of the tumor-produced MUC16/CA125 protein has a negative impact on the efficacy of rituximab.

Key Points: 
  • Recent clinical evidence suggests that high serum levels of the tumor-produced MUC16/CA125 protein has a negative impact on the efficacy of rituximab.
  • Navrogen will present data showing NAV-006's superior efficacy over rituximab in animal models of human NHL.
  • "We have engineered a trastuzumab-drug conjugate variant with superior cytotoxicity against ICAM-1 positive cancer cells.
  • We are now building a portfolio of enhanced ADCs using this platform to advance internal as well as partnered ADC programs".

PLT Introduces Novel, Patented, Broad Spectrum Immune Health Ingredient

Retrieved on: 
Wednesday, April 26, 2023
PLT, Drink, Humoral immunity, Clinical trial, Serum, Immunity, Innovation, Biomarker, Tablet, Plant, Capsule, Immune system, Immunoglobulin G, Phytochemical, Polysaccharide, Female, Terminalia, Vaccine

MORRISTOWN, N.J., April 26, 2023 /PRNewswire/ -- PLT Health Solutions, Inc is launching a novel ingredient to support immune health. Called Spectramune® Immune Defense Complex, the ingredient is a patented, synergistic combination of ashwagandha (Withania somnifera) and Haritaki (Terminalia chebula). Clinical study data looking at immune biomarkers showed significant improvements across a broad range of immune cells – targeting innate, cell-mediated and humoral immunity. These markers are linked to the first line of immune defense (innate), support for the slower immune response that the body mounts in response to unfamiliar pathogens (cell-mediated) and support for the remembered/antibody response from exposure to new pathogens and vaccinations (humoral). Spectramune is mild tasting and 70-80% water-soluble, allowing it to be used in a variety of product forms from tablets, capsules and soft gels to functional foods and beverages - and in a broad range of immune support formulations.

Key Points: 
  • New Spectramune® Immune Defense Complex is Clinically Demonstrated to Enhance Innate, Cell-Mediated and Humoral Immunity
    MORRISTOWN, N.J., April 26, 2023 /PRNewswire/ -- PLT Health Solutions, Inc is launching a novel ingredient to support immune health.
  • Clinical study data looking at immune biomarkers showed significant improvements across a broad range of immune cells – targeting innate, cell-mediated and humoral immunity.
  • According to Seth Flowerman, President & CEO of PLT Health Solutions, the new ingredient was developed to meet industry and consumer interest for a novel solution that provides comprehensive immune health support.
  • Formulators of immune health products can use Spectramune as a foundational ingredient or in combination with existing formulas to address a wide range of a consumer's immune health needs," he added.

Cancer Advances, Inc. Announces Issuance of New U.S. Patent

Retrieved on: 
Tuesday, February 28, 2023
Cancer, Survival, Fibrosis, Pancreatic cancer, Gastrointestinal cancer, Research, Neoplasm, Patient, Patent, Therapy, PAS, GI, Tumor microenvironment, Antibody, Humoral immunity, Pharmaceutical industry, Gastrin

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No.

Key Points: 
  • DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No.
  • The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject.
  • The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor.
  • Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers.

Portage Biotech Provides Research and Development Update and Announces NASDAQ Listing Approval

Retrieved on: 
Thursday, February 11, 2021
CTAG1B, Proteins, Immunotherapy, NASDAQ, Humoral immunity, Branches of biology, Health sciences, Health

Portage also announced that it has received approval from the NASDAQ Capital Market ("NASDAQ") to list its common shares on the NASDAQ exchange, and expects to commence trading February 25, 2021 under the symbol "PRTG."

Key Points: 
  • Portage also announced that it has received approval from the NASDAQ Capital Market ("NASDAQ") to list its common shares on the NASDAQ exchange, and expects to commence trading February 25, 2021 under the symbol "PRTG."
  • Portage aims to catalyze research and development to produce a higher volume of quality clinical programs through its development strategy, commercial insights, and deep network of industry relationships.
  • The humoral and cellular immune responses along with the restricted expression of NY-ESO-1 make it a good target for cancer immunotherapies.
  • The trial has been approved by the regulatory agency and institutional ethics committee and is ready to start recruiting patients.

Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2

Retrieved on: 
Monday, December 14, 2020
Medical specialties, Medicine, Health, Immunology, Sarbecovirus, BNT162b2, Pfizer, Medical research, Immune system, Severe acute respiratory syndrome, Humoral immunity, BioNTech

The study results demonstrate that BNT162b2 elicits a combined adaptive humoral and cellular immune response against SARS-CoV-2 and provide insights into the composite nature of BNT162b2-induced T cell immunity.

Key Points: 
  • The study results demonstrate that BNT162b2 elicits a combined adaptive humoral and cellular immune response against SARS-CoV-2 and provide insights into the composite nature of BNT162b2-induced T cell immunity.
  • These results from the ongoing German Phase 1/2 study help illustrate the multiple arms of the immune system that are activated to fight SARS-CoV-2 by the vaccine candidate BNT162b2.
  • The ongoing non-randomized open-label Phase 1/2 trial (NCT04380701) is being conducted in Germany in parallel to the Phase 1/2/3 trial (NCT04368728) that started in the U.S.
  • BNT162b2 immune sera efficiently neutralized 19 pseudo-viruses, indicating the potential for broad BNT162b2-elicited protection against reported mutations.

INOVIO to Present at Upcoming Investor Conferences in September

Retrieved on: 
Tuesday, September 1, 2020
Medical specialties, Branches of biology, Immunology, Biology, Immune system, Gene delivery, Inovio Pharmaceuticals, Antigen, Humoral immunity, Antibody, V(D)J recombination, Plasmid

Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events page and may be accessed by visiting INOVIO's website at http://ir.inovio.com/investors/events/default.aspx .

Key Points: 
  • Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events page and may be accessed by visiting INOVIO's website at http://ir.inovio.com/investors/events/default.aspx .
  • INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA.
  • The antigen is processed naturally in the cell and triggers a specific T cell and antibody-mediated immune responses.
  • INOVIO's DNA medicines are transient, and do not interfere with or change in any way an individual's own DNA.

Cytocom, Inc. Announces Agreement to Reacquire Rights to Lead Drug Candidate CYTO-201 and CYTO-401 in Emerging Markets

Retrieved on: 
Thursday, August 20, 2020
Immunology, Immunotherapy, Immune system, Humoral immunity

The agreement contemplates the execution of certain additional documents and consents in order to complete the assumption of various liabilities from noteholders and other creditors.

Key Points: 
  • The agreement contemplates the execution of certain additional documents and consents in order to complete the assumption of various liabilities from noteholders and other creditors.
  • The company does not anticipate any issues with the closing of this transaction, which is expected by the end of the third quarter 2020.
  • Cytocom is now reacquiring this license in exchange for the assumption of up to approximately $5 million of Immune liabilities.
  • The company's immunomodulatory platform technology seeks to restore a balance between the cellular (Th1) and the humoral (Th2) immune systems.

OncoSec's Novel COVID-19 Vaccine Candidate Featured in 'Straight Talk' Program by NBC TV in Portland, Oregon

Retrieved on: 
Monday, July 13, 2020
Immunology, Immune response, Humoral immunity, Cell-mediated immunity, Immunity, Applied sciences, Malaria vaccine

You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-t...

Key Points: 
  • You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-t...
    OncoSec and researchers at Providence Cancer Institute previously announced a collaboration to conduct a first-in-human trial of OncoSec's CORVax12 vaccine candidate.
  • CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.
  • Researchers believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.
  • OncoSec's lead product candidate, TAVO, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions.

Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals

Retrieved on: 
Thursday, April 16, 2020
Immunology, Medicine, Health, Adjuvant, Medication, Humoral immunity, Antibody

CoVaccine HT is a novel adjuvant, which has been shown to enhance both cell-mediated and antibody-mediated immunity.

Key Points: 
  • CoVaccine HT is a novel adjuvant, which has been shown to enhance both cell-mediated and antibody-mediated immunity.
  • "BTG has a long track record of technological innovation in the production of antibodies for rescue medicines.
  • We're pleased that, in the hands of Soligenix, CoVaccine HT could potentially play a role in helping to address the current pandemic," said Anthony Higham, President of BTG.
  • The agreement was executed between Soligenix and Protherics Medicines Development, one of the companies that make up the BTG Specialty Pharmaceutical business, which owns the CoVaccine HT intellectual property.

OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12, an Investigational Vaccine to Prevent COVID-19, Combining an Enhanced "Spike" DNA Sequence and TAVO™

Retrieved on: 
Monday, April 6, 2020
Medical specialties, Immunology, Medicine, Branches of biology, Electroporation, Humoral immunity, Vaccine, Immune response, Immunity, Cell-mediated immunity, Immunologic adjuvant

CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.

Key Points: 
  • CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.
  • We believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.
  • Importantly, we believe the delivery of CORVax12 using OncoSec's electroporation system may allow for highly effective DNA transfer to drive this investigational vaccine."
  • Dr. Leidner continued, "Providence is among the U.S.'s largest, not-for-profit network of hospitals and includes 51 hospitals in Alaska, Washington, Oregon, Montana and California.